Tag: KDC-MN-1560

  • Empagliflozin

    Selective sodium-glucose co-transporter 2 (SGLT2) inhibitor of the C-aryl glucoside structural class

    A highly selective SGLT2 inhibitor developed by Boehringer Ingelheim as an oral antihyperglycemic agent, distinguished from other gliflozins by the highest SGLT2-to-SGLT1 selectivity ratio in the class, landmark cardiovascular and renal outcome trial data, and regulatory approval across type 2 diabetes, heart failure with reduced and preserved ejection fraction, and chronic kidney disease.

    Abstract

    Empagliflozin (BI 10773, marketed as Jardiance) is a potent, orally bioavailable, selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) protein expressed in the S1 and S2 segments of the renal proximal tubule, where it mediates approximately 90 percent of filtered glucose reabsorption. The compound is a C-aryl glucoside bearing a chlorophenyl core linked to a tetrahydrofuranyloxy-substituted benzyl moiety, and it exhibits the highest selectivity for SGLT2 over the intestinal isoform SGLT1 among the marketed gliflozins, with a selectivity ratio exceeding 2500-fold in heterologous expression systems. Empagliflozin was developed by Boehringer Ingelheim in collaboration with Eli Lilly and Company, received initial regulatory approval in 2014 for the treatment of type 2 diabetes mellitus, and has since undergone one of the most consequential clinical development programs in modern cardiometabolic medicine. The EMPA-REG OUTCOME trial (2015), enrolling 7020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 35 percent reduction in hospitalization for heart failure, results that fundamentally altered the treatment paradigm for type 2 diabetes and prompted regulatory label expansions for cardiovascular risk reduction. The EMPEROR-Reduced trial (2020) demonstrated a 25 percent reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction regardless of diabetes status, while the EMPEROR-Preserved trial (2021) extended this benefit to patients with heart failure and preserved ejection fraction, a population for which few prior therapies had demonstrated efficacy. The EMPA-KIDNEY trial (2022) demonstrated a 28 percent reduction in the composite of kidney disease progression or cardiovascular death in 6609 patients with chronic kidney disease across a broad range of eGFR values. Pharmacokinetics are characterized by rapid oral absorption with peak plasma concentrations at approximately 1.5 hours, steady-state plasma protein binding of 80 to 86 percent, a terminal elimination half-life of approximately 12.4 hours supporting once-daily dosing, and metabolism predominantly through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 without clinically meaningful cytochrome P450 involvement. The compound has minimal drug-drug interaction potential and does not require dose adjustment for hepatic impairment or mild-to-moderate renal impairment, although efficacy on glycemic endpoints diminishes at lower eGFR values where the filtered glucose load is reduced. The principal adverse events are genital mycotic infections (occurring in approximately 5 to 10 percent of female patients and 1 to 5 percent of male patients), urinary tract infections, volume depletion (particularly in elderly patients and those on concomitant diuretics), and rare but serious events including euglycemic diabetic ketoacidosis and necrotizing fasciitis of the perineum (Fournier gangrene). This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.